ArticleCancer medicine2026
Integrated Analysis of Glycolytic and Cholesterogenic Genes Identifies Prognostic Metabolic Subgroup of IDH Wild-Type Glioblastoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioblastoma (GBM) is a markedly heterogeneous intracranial tumor characterized by poor prognosis. While distinctive glycolysis and cholesterol synthesis capacities exist within its microenvironment, comprehensive profiling of these metabolic traits remains lacking. Using genomic, transcriptomic, and clinical data from 364 IDH wild-type GBM cases across The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) cohorts-supplemented by the Cancer Cell Line Encyclopedia (CCLE) and TCGA cancer cell line data-we performed consensus clustering using glycolytic and cholesterogenic genes. This identified four metabolic subgroups: cholesterogenic, glycolytic, mixed, and quiescent. The mixed subgroup demonstrated the poorest prognosis, whereas the cholesterogenic subgroup exhibited the most favorable outcome. Notably, high CD8+ T cell proportions correlated with worse prognosis in cholesterogenic and quiescent groups, while elevated CD4+ naïve T cells and mast cells associated with poorer outcomes in glycolytic and mixed groups, respectively. The glycolytic subgroup showed lowest expression of mitochondrial pyruvate carriers (MPC1/MPC2), and the mixed subgroup exhibited minimal methylation. Functionally, pharmacological inhibition of MPC with UK-5099 increased glycolytic flux and lactate production, most prominently in cholesterogenic-pattern GBM cells, and conditioned media from MPC-inhibited or glycolytic GBM cells promoted microglial polarization toward an immunosuppressive phenotype, indicating that MPC1/2 may remodel the glycolysis-cholesterol metabolic axis to shape the microglial immune phenotype. Metabolism stratification by glycolytic/cholesterogenic profiles provides novel insights into IDH wild-type GBM subtypes, supplements existing prognostic frameworks, and may inform the rational design of future metabolism-directed strategies, although direct therapeutic validation will be required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.